Search clinical trials for: FXI

Total 34 results

Regeneron Pharmaceuticals

Not yet recruiting

A Trial to Learn How Well REGN7508 Works for Preventing Blood Clots After a Knee Replacement in Adult Participants (ROXI-VTE II)

Venous Thromboembolism
Regeneron Pharmaceuticals

Not yet recruiting

A Trial to Learn How Well REGN9933 and REGN7508 Work for Preventing Blood Clots, and How Safe They Are, in Adults Who Have a Peripherally Inserted Central Catheter (PICC) (ROXI-CATH)

Venous Thromboembolism
Sirnaomics

Recruiting

Single Ascending Dose of FXI-GalNAc-siRNA in Healthy Subjects

FXI

United States, Canada
Anthos Therapeutics, Inc.
Itreas

Recruiting

A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTE (ASTER)

Venous Thromboembolism | Pulmonary Embolism | Deep Venous Thrombosis

Austria, United States, Taiwan, Australia, China, Spain, Japan, Canada, Ireland, Italy, Korea, Republic of, France, Switzerland, Hungary, Netherlands, Latvia, Germany, Norway, Sweden, Czechia, United Kingdom
Anthos Therapeutics, Inc.
Itreas

Recruiting

A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE (MAGNOLIA)

Venous Thromboembolism | Pulmonary Embolism | Deep Venous Thrombosis

Austria, United States, Taiwan, Australia, China, Spain, Korea, Republic of, Italy, Hungary, France, Netherlands, Latvia, Ireland, Germany, United Kingdom, Canada, Norway, Sweden, Czechia, Switzerland
Regeneron Pharmaceuticals

Completed

A Trial to Learn How Well REGN9933 Works for Preventing Blood Clots After Knee Replacement Surgery in Adult Participants

Venous Thromboembolism

Poland, Latvia, Canada, Belgium, Bulgaria, Hungary, Lithuania
OHSU Knight Cancer Institute
National Heart, Lung, and Blood Institute (NHLBI); Oregon Health and Science...

Terminated

Xisomab 3G3 for the Prevention of Catheter-Associated Thrombosis in Patients With Cancer Receiving Chemotherapy

Malignant Solid Neoplasm | Lymphoma | Plasma Cell Myeloma

United States
Charite University, Berlin, Germany
Shire International GmbH

Active, not recruiting

Lanadelumab in FXII-associated Cold Autoinflammatory Syndrome (FACAS) (LANA-FXII)

Hereditary Autoinflammatory Disease

Germany
Novo Nordisk A/S

Enrolling by invitation

A Study of Safety and Effectiveness of NovoThirteen® (rFXIII) During Treatment of Congenital FXIII Deficiency in Japan

Congenital Bleeding Disorder | Congenital FXIII Deficiency

Japan
eXIthera Pharmaceuticals

Withdrawn

COVID-19 ThromboprophylaXIs Study of Novel FXIa Inhibitor Frunexian (EP-7041) in ICU Patients

Covid19 | Thrombopenia

United States
Merck Sharp & Dohme LLC

Active, not recruiting

Global Study of MK-2060 (Anti-Factor XI Monoclonal Antibody) in Participants With End Stage Renal Disease Receiving Hemodialysis (FXI Hemodialysis Study) (MK-2060-007)

Kidney Failure, Chronic | End-Stage Renal Disease | End-Stage Kidney Disease

United States, Argentina, Australia, Brazil, Bulgaria, Canada, Czechia, Germany, Greece, Italy, Portugal, Puerto Rico, Romania, Russian Federation, Sweden
Bayer
Population Health Research Institute

Completed

Study to Gather Information About Proper Dosing and Safety of the Oral FXIa Inhibitor BAY 2433334 in Patients Following a Recent Non Cardioembolic Ischemic Stroke Which Occurs When a Blood Clot Has Formed Somewhere in the Human Body (But Not in the Heart) Travelled to the Brain. (PACIFIC-STROKE)

Acute Non-cardioembolic Ischemic Stroke

Spain, Japan, Australia, Czechia, Sweden, United Kingdom, Netherlands, Belgium, Russian Federation, Hungary, Slovakia, China, Germany, Switzerland, France, Poland, Denmark, United States, Austria, Bulgaria, Finland, Italy, Portugal
Bayer

Completed

Study to Gather Information About the Proper Dosing and Safety of the Oral FXIa Inhibitor BAY 2433334 in Patients Following an Acute Heart Attack (PACIFIC-AMI)

Acute Myocardial Infarction

Spain, Japan, Belgium, United States, Czechia, Hungary, Switzerland, Netherlands, Germany, Austria, Poland, Italy, Sweden, United Kingdom
Ionis Pharmaceuticals, Inc.
Bayer

Completed

A Study of ISIS 416858 Administered Subcutaneously to Participants With End-Stage Renal Disease (ESRD) on Hemodialysis (EMERALD)

End-stage Renal Disease (ESRD)

Spain
Bayer

Completed

Study to Gather Information About the Proper Dosing of the Oral FXIa Inhibitor BAY 2433334 and to Compare the Safety of the Study Drug to Apixaban, a Non-vitamin K Oral Anticoagulant (NOAC) in Patients With Irregular Heartbeat (Atrial Fibrillation) That Can Lead to Heart-related Complications. (PACIFIC-AF)

Atrial Fibrillation (AF)

Spain, Belgium, Latvia, Italy, Switzerland, Canada, Austria, Japan, Czechia, Hungary, Netherlands, Sweden, France, United Kingdom
Ionis Pharmaceuticals, Inc.

Completed

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of IONIS FXI-LRx in up to 84 Healthy Volunteers

Healthy Participants

Canada
Patricia Duque González

Completed

Impact of Acquired FXIII Deficiency on Morbidity and Mortality

Acquired Factor XIII Deficiency Disease

Spain
Novo Nordisk A/S

Completed

Use of rFXIII in Treatment of Congenital FXIII Deficiency, a Prospective Multi-centre Observational Study (mentor™6)

Congenital Bleeding Disorder | Congenital FXIII Deficiency

Spain, United States, Canada, Italy, United Kingdom, Hungary
Children's Hospital of Orange County
CSL Behring

Completed

Clinical Trial of Factor XIII (FXIII) Concentrate

Hemophilia | Factor XIII Deficiency

United States
Novo Nordisk A/S

Completed

Safety of Monthly Recombinant Factor XIII Replacement Therapy in Subjects With Congenital Factor XIII Deficiency: An Extension to Trial F13CD-1725 (mentor™2)

Congenital Bleeding Disorder | Congenital FXIII Deficiency

France, United States, Israel, Spain, Switzerland, Germany, Canada, Japan, United Kingdom, Italy, Finland, Austria
Novo Nordisk A/S

Completed

Evaluation of Recombinant Factor XIII for Prevention of Bleeding in Patients With FXIII Inherited Deficiency

Congenital Bleeding Disorder | Congenital FXIII Deficiency

United States, Israel, Austria, Spain, Switzerland, Germany, Canada, France, United Kingdom, Italy, Finland
Novo Nordisk A/S

Completed

Safety of a Single Intravenous Dose of Recombinant Factor XIII in Children With Congenital FXIII A-subunit Deficiency (mentor™4)

Congenital Bleeding Disorder | Congenital FXIII Deficiency

United States, Israel, United Kingdom
Novo Nordisk A/S

Completed

Safety and Pharmacokinetics of Recombinant Factor XIII in Healthy Volunteers

Healthy | Congenital Bleeding Disorder | Congenital FXIII Deficiency

United Kingdom
Novo Nordisk A/S

Completed

Safety and Pharmacokinetics of Recombinant Factor XIII in Patients With Congenital Factor Xlll Deficiency

Congenital Bleeding Disorder | Congenital FXIII Deficiency

United States
Ionis Pharmaceuticals, Inc.
Bayer

Completed

A Study of Safety, PK, & PD of ISIS 416858 Administered Subcutaneously to Patients With End-Stage Renal Disease on Hemodialysis

End-stage Renal Disease (ESRD)

Canada
Novo Nordisk A/S

Completed

Comparison of a Blood Clotting Drug (Recombinant Factor XIII) Produced by Two Different Manufacturers in Healthy Male Subjects

Healthy | Congenital Bleeding Disorder | Congenital FXIII Deficiency

United Kingdom
Johnson & Johnson Pharmaceutical Research & Development...

Withdrawn

A Study to Evaluate Folate Levels in Women Taking Oral Contraceptives

Nervous System Malformations | Neural Tube Defects | Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Novo Nordisk A/S

Completed

Safety and Efficacy of Monthly Replacement Therapy With Recombinant Factor XIII (rFXIII) in Paediatric Subjects With Congenital Factor XIII A-subunit Deficiency (mentor™5)

Congenital Bleeding Disorder | Congenital FXIII Deficiency

United Kingdom, Israel, United States
Medical University Innsbruck

Terminated

RETIC Trial: Reversal of Trauma Induced Coagulopathy Using Coagulation Factor Concentrates or Fresh Frozen Plasma

Major Trauma

Austria
Ionis Pharmaceuticals, Inc.

Completed

Active Comparator-Controlled Study to Assess Safety and Efficacy of ISIS-FXIRx in Total Knee Arthroplasty

Venous Thromboembolism

Bulgaria, Canada, Latvia, Russian Federation, Ukraine
Novo Nordisk A/S

Completed

Safety and Pharmacokinetics of Recombinant Factor XIII Administration in Healthy Volunteers

Healthy | Congenital Bleeding Disorder | Congenital FXIII Deficiency

United Kingdom
CSL Behring

Completed

An Open Enrollment Study of Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency

Factor XIII Deficiency

United States
CSL Behring

Completed

A Study of Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency

Factor XIII Deficiency

United States, Spain
CSL Behring

Completed

A Study of the Use of Factor XIII Concentrate in Patients With Inherited FXIII Deficiency

Factor XIII Deficiency

United States, Spain

Search clinical trials for: FXI

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Norway

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations